Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CS MEDICA’s clinical trial Phase III results from the intermediate report on NGA-01 (CANNASEN®CBD Arthritis Gel) against placebo

Today, September 10[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) can announce that the CANNASEN®CBD Arthritis Gel (NGA-01) has, after conducting the final efficacy analysis in the ongoing Phase III trial, met all the trial’s primary efficacy endpoints. Analysis of the data indicates that CANNASEN®CBD Arthritis Gel (NGA-01) has an efficacy rate of 89 percent in reduction of pain in joints of participants with Osteoarthritis with joint pain in any of the joints; knee, hip, ankle, elbow, and shoulder. The data of the trial shows that the CANNASEN®CBD Arthritis Gel (NGA-01) was well

CS MEDICA A/S issue of units prior to listing was oversubscribed

On August 31[st], 2021, the subscription period in CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) IPO of units (shares and consideration free warrants) prior to the planned listing on Spotlight Stock Market ended. The initial part of the IPO of units was subscribed to a total of approximately DKK 35.2 million, corresponding to a subscription ratio of approximately 158 percent. The Company will thus receive approximately DKK 22.3 million of which approximately DKK 3.9 million pertains to bridge loan, and approximately DKK 0.8 million is attributable to compensation (in the form of units) to

Release of application and dermatological test results for CANNASEN CBD Psoriasis lotion

Today, August 19[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) announces a good result on two tests performed at the Dermatology Clinic of the Medical University of Gdańsk, an application test and a dermatological test on the Company’s Psoriasis lotion.Lone Henriksen comments “Irritating and allergenic properties. We are very excited about these positive results as it follows our targets in preparation for the market launch of the product in H1 2021/2022.” These results confirm that Psoriasis lotion show positive effects and can be used as an adjunctive treatment product. It

Today CS MEDICA will attend a webinar at Nordnet Live and informs on Biostock article

Today, August 19[th], 2021, CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) announces CEO Lone Henriksen and CFO Gitte Henriksen will present the Company and talk about the upcoming listing at the webinar Nordnet Live, today at 15:30. Further, Biostock has released an article presenting the Company and the expansion across Europe.Webinar Nordnet LiveNordnet Live will today, on August 19[th] at 15.30, host a webinar and receive a visit by CS MEDICA’s CEO Lone Henriksen and CFO Gitte Henriksen, where they will present the Company and talk about CS MEDICA's upcoming IPO. There will be an

The subscription period in CS MEDICA A/S’s issue of units starts today

Today, August 17[th], 2021, is the first day of the subscription period in CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) issue of units prior to the planned listing on Spotlight Stock Market. The subscription period lasts until August 31[st], 2021. A fully subscribed issue of units will initially provide CS MEDICA with approx. DKK 22.3 million and an additional approx. DKK 10.8 million at a later stage if all warrants of series TO 1 are exercised. Prior to the issue of units, CS MEDICA has received subscription commitments corresponding to approx. 60 percent of the initial issue volume. The

CS MEDICA A/S approved for listing at Spotlight Stock Market, publishes prospectus

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby announces that the Company has been approved for listing at Spotlight Stock Market. The approval is given under the condition that CS MEDICA, a Danish medico cannabis company, raises the minimum limit in the Company's forthcoming issue of units and that the Company obtains a sufficient number of shareholders, in accordance with Spotlight Stock Market’s regulations. Further, CS MEDICA today publishes the prospectus for the upcoming issue of units (shares and free of charge warrants), which amounts to a total of approx. DKK 33.1 million. The

CS MEDICA A/S announces its intention to list its shares on Spotlight Stock Market

CS MEDICA A/S (”CS MEDICA” or the ”Company”) is a Danish medico cannabis company committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids The Company hereby announces its intention to launch an initial public offering of its shares (the “IPO” or the “Offer”) and to list its shares on Spotlight Stock Market (“Spotlight”) in Q3 2021. CS MEDICA has engaged Sedermera Fondkommission to act as financial advisor, Markets & Corporate Law Nordic AB as legal advisor, Nordnet Bank AB as selling agent, and Nordic Issuing to provide

There are no items matching the current filter
There are no more items matching the current filter
Back to top